Dongcheng Pharmaceutical (002675.SZ): Net profit of 64.327 million yuan in the first quarter increased 28.38% year-on-year

Gelonghui, April 26 | Dongcheng Pharmaceutical (002675.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 647 million yuan, down 23.90% year on year; net profit attributable to shareholders of listed companies was 64.327 million yuan, up 28.38% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 54.849,97 million yuan, up 29.40% year on year; basic earnings per share were 0.0780 yuan.

Gelonghui FinanceApr 26 20:32

Lanfan Healthcare (002382.SZ) announced first-quarter results with a net loss of 98.9196 million yuan

According to the Zhitong Finance App, Lanfan Healthcare (002382.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 1,455 billion yuan, an increase of 32.96% over the previous year. The net loss attributable to shareholders of the listed company was RMB 98.9196 million. Net loss of $124 million after deducting non-recurring profit and loss attributable to shareholders of listed companies.

Zhitong FinanceApr 26 18:18

CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2%

China Resources Double-Crane Pharmaceutical (SHA:600062) posted an 11% year-over-year increase in attributable net profit in the first quarter of 2024 to 416.1 million yuan from 374.9 million yuan, th

MT NewswiresApr 26 14:09

CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication

China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, China Resources Shuanghe Limin Pharmaceutical (Jinan), will conduct clinical trials on pregabalin extended-release tablets after receiv

MT NewswiresApr 26 14:04

The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.

The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.

Zhitong FinanceApr 26 10:09

China Resources Shuanghe (600062): Another success, great results, and steady infusions/formulations

Another good result was achieved under a high base. The large infusion/formulation was stable, with a target price of 25.74 yuan. The “purchase” of China Resources Shuanghe achieved revenue of 2.84 billion yuan (+2.3% yoy) in 1Q24, and a net profit of 420 million yuan to the mother

華泰證券Apr 26 09:31